A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Abbott2 个研究点分布在 1 个国家目标入组 150 人开始时间: 2003年12月最近更新: 2006年10月2日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Abbott
入组人数: 150
试验地点: 2
主要终点: Proportion of subjects with a plasma HIV RNA level below 50 copies/mL at Week 96.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

Proportion of subjects with a plasma HIV RNA level below 50 copies/mL at Week 96.

次要结局

未报告次要终点

研究者

发起方

Abbott

申办方类型

Industry

研究点 (2)

Loading locations...

相似试验

撤回

2 期

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected SubjectsHIV InfectionHepatitis C

NCT00121017Abbott200

已完成

4 期

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen FailureHIVAIDSLopinavirTreatment Failure

NCT01189695Bamrasnaradura Infectious Diseases Institute63

已完成

3 期

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)Human Immunodeficiency Virus Infection

NCT00711009Abbott206

已完成

2 期

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceHIV Infections

NCT00046033National Institute of Allergy and Infectious Diseases (NIAID)118

进行中（未招募）

1 期

A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Raltegravir 400 mg Twice-Daily in Antiretroviral-Naïve, HIV-1 Infected Subjects

EUCTR2008-000881-22-FRAbbott GmbH & Co. KG200